Research Topics
| Mark A MungerSummaryAffiliation: University of Utah Country: USA Publications
| Collaborators
|
Detail Information
Publications
Safety of prescribing PDE-5 inhibitors via e-medicine vs traditional medicineMark A Munger
Department of Internal Medicine, Universityof Utah, Salt Lake City 84112 5820, USA
Mayo Clin Proc 83:890-6. 2008..To determine the safety of a US-based, state-regulated Internet system vs a multispecialty primary care system for prescribing phosphodiesterase type 5 (PDE-5) inhibitors for erectile dysfunction...
Epidemiology and practice patterns of acute decompensated heart failureMark A Munger
Department of Pharmacy Practice and Internal Medicine, University of Utah, UTAH Affiliated Heart Failure Prevention and Treatment Program, 30 South, 2000 East, Room 258, Salt Lake City, UT 84112 5820, USA
Am J Health Syst Pharm 60:S3-6. 2003....
Medication nonadherence: an unrecognized cardiovascular risk factorMark A Munger
Departments of Pharmacotherapy and Internal Medicine, University of Utah, Salt Lake City, Utah, USA
MedGenMed 9:58. 2007..Numerous strategies to improve medication adherence are available, from enhancing patient education to providing medication adherence information to the healthcare team and will be discussed in this article...- Controversy and conflict in the treatment of acute decompensated heart failure: nesiritide as evidence-based treatmentMark A Munger
Department of Pharmacotherapy and Internal Medicine, University of Utah, Salt Lake City, Utah 84112, USA
Pharmacotherapy 27:619-25. 2007.... - Management of acute decompensated heart failure: treatment, controversy, and future directionsMark A Munger
Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah 84112 5820, USA
Pharmacotherapy 26:131S-138S. 2006..This article highlights our current understanding of acute decompensated heart failure, discusses the controversy surrounding currently available new vasoactive treatments, and details future potential therapies... - Misoprostol effects on diclofenac-induced cardiorenal changes in salt-sensitive patients with hypertension: the MEDIC StudyMark A Munger
Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah 84112 5820, USA
Pharmacotherapy 28:834-42. 2008..To determine whether coadministration of misoprostol with the nonsteroidal antiinflammatory drug diclofenac lessens the increase in blood pressure and improves the alterations in renal hemodynamics induced by diclofenac... - New agents for managing hyponatremia in hospitalized patientsMark A Munger
College of Pharmacy, University of Utah, 30 South 2000 East, Room 201, Salt Lake City, UT 84112 5820, USA
Am J Health Syst Pharm 64:253-65. 2007..An overview of hyponatremia is provided, including its pathophysiology, clinical manifestations, signs and symptoms, and treatment, particularly with arginine vasopressin (AVP)-receptor antagonists... - Aliskiren for renin inhibition: a new class of antihypertensivesBenjamin W Van Tassell
Experimental Cardiovascular Pharmacotherapy, Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA
Ann Pharmacother 41:456-64. 2007..To review the safety, efficacy, pharmacology, pharmacokinetics, and drug interactions of aliskiren for the treatment of mild-to-moderate hypertension... - Assessment of time to follow-up visits in newly-treated hypertensive patients using an electronic medical record databaseDiana I Brixner
University of Utah College of Pharmacy, Department of Pharmacotherapy, Salt Lake City, UT 84112, USA
Curr Med Res Opin 26:1881-91. 2010..Findings were compared to treatment guidelines which recommend monthly follow-up in treatment naive patients until blood pressure (BP) levels are controlled... - Polypharmacy and combination therapy in the management of hypertension in elderly patients with co-morbid diabetes mellitusMark A Munger
College of Pharmacy, University of Utah, Salt Lake City, Utah 84112, USA
Drugs Aging 27:871-83. 2010..Rational combination therapy can maximize BP control along with glycaemic control and help maximize the benefits of polypharmacy on outcomes in elderly patients with hypertension and co-morbid diabetes... - Combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart failureBenjamin W Van Tassell
Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA
Pharmacotherapy 28:1523-30. 2008..Compartmentation of cyclic adenosine 3',5'-monophosphate signaling may prove critical in determining myocardial response to combination therapy... - Faculty turnover within academic pharmacy departmentsOrly Carter
Pharmacy Services, University of Utah Hospitals and Clinics, Salt Lake City, UT 84132 1915, USA
Ann Pharmacother 37:197-201. 2003..Previous investigations studied job satisfaction among faculty members, but have not evaluated faculty retention and turnover among academic pharmacy departments... - Carvedilol increases blood pressure response to phenylephrine infusion in heart failure subjects with systolic dysfunction: evidence of improved vascular alpha1-adrenoreceptor signal transductionBenjamin W Van Tassell
Department of Pharmacotherapy, University of Utah, Salt Lake City, UT 84112, USA
Am Heart J 156:315-21. 2008..We examined alpha(1)-AR signal transduction by repeat phenylephrine (PE) infusions in patients with HF receiving chronic carvedilol therapy... - High-impact articles related to the management of heart failure: 2008 updateCynthia A Jackevicius
Department of Pharmacy Practice and Administration, College of Pharmacy, Western University of Health Sciences, Pomona, California, USA
Pharmacotherapy 29:82-120. 2009..In addition, consensus documents formed by expert panels are reviewed. This compilation may serve as a teaching tool, reference resource, or update of the literature for pharmacy clinicians, physicians, and students... - Chronically inhaled salmeterol improves pulmonary function in heart failureTien M H Ng
Department of Pharmacy Practice, University of Utah Health Sciences Center, Salt Lake City, UT, USA
J Cardiovasc Pharmacol 40:140-5. 2002..The plasma half-life of salmeterol may be prolonged in heart failure patients, thus leading to accumulation at steady-state... - Atherothrombosis: epidemiology, pathophysiology, and preventionMark A Munger
Department of Pharmacy Practice, College of Pharmacy, University of Utah, Salt Lake City, USA
J Am Pharm Assoc (2003) 44:S5-12; quiz S12-3. 2004..Secondary prevention of an ischemic event in an affected arterial bed confers the added benefit of primary prevention against potential ischemic events in other arterial beds... - Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapyWaymon Drummond
Renaissance Research and Hypertension of Texas, Dallas, TX 75235 6209, USA
J Clin Hypertens (Greenwich) 9:742-50. 2007.... - High-impact articles related to the pharmacotherapeutic management of systolic heart failureTien M H Ng
School of Pharmacy, University of Southern California, Los Angeles, California, 90033, USA
Pharmacotherapy 24:1594-633. 2004..This compilation may serve as a teaching tool, reference resource, or update of the literature for pharmacy clinicians, physicians, and students...